Researcher
Chris Marine
- Disciplines (Flanders Institute for Biotechnology):Analysis of next-generation sequence data, Cell death, Cancer biology
- Disciplines (KU Leuven):Morphological sciences, Oncology
Affiliations
- Laboratory for Molecular Cancer Biology (VIB-KU Leuven) (Division)
Responsible
From1 Jan 2017 → Today - VIB-KU Leuven Center for Cancer Biology (Research Center)
Responsible
From1 Jan 2017 → Today - Marine Lab (Research group)
Responsible
From1 Jan 2017 → Today - Laboratory for Molecular Cancer Biology (VIB-KU Leuven) (Division)
Member
From1 Oct 2013 → Today - Department of Human Genetics (Department)
Member
From1 Oct 2009 → 31 Dec 2016
Projects
1 - 10 of 63
- Understanding and targeting melanoma mesenchymal-like cells to improve response to immunotherapyFrom1 Jan 2024 → TodayFunding: FWO research project (including WEAVE projects)
- Deciphering molecular mechanisms and intercellular communication networks underlying the emergence of the metastasis-initiating melanoma cellFrom1 Nov 2023 → TodayFunding: FWO fellowships
- Spatio-temporal dissection of inter-cellular melanoma communication networks that contribute to resistance to immunotherapy.From1 Oct 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Empowering precision medicine in melanoma: Exploring the potential of an implantable microdevice for large-scale drug screening in vivoFrom12 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Microfluidic tools to study single-cell responses and cell-cell communication in cancer applicationsFrom1 Sep 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Identification of universal biomarkers of metastatic melanoma in CTCsFrom30 May 2023 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Detection and prevention of early metastatic dissemination of melanomaFrom1 Jan 2023 → TodayFunding: Foundations, funds and other with scientific goal
- Dissecting the heterotypic cell communication networks at the perivascular niche to detect andintercept the early metastatic processFrom1 Jan 2023 → TodayFunding: BOF - iBOF
- Dissecting the cellular and molecular interaction networks that promote melanoma stemness at the perivascular niche.From1 Oct 2022 → TodayFunding: FWO senior postdoctoral fellowship
- Circulating tumor cells as a target of anti-metastatic treatment in melanoma.From1 Sep 2022 → TodayFunding: FWO Strategic Basic Research Grant
Publications
11 - 20 of 154
- Pharmacological induction of membrane lipid poly-unsaturation sensitizes melanoma to ROS inducers and overcomes acquired resistance to targeted therapy(2023)
Authors: Ali Talebi, Vincent de Laat, Xander Spotbeen, Jonas Dehairs, Ginevra Doglioni, David Nittner, Tania Roskams, Patrizia Agostinis, Oliver Bechter, Veerle Boecxstaens, et al.
- Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma(2023)
Authors: Chris Marine
- A palmitate-rich metastatic niche enables metastasis growth via p65 acetylation resulting in pro-metastatic NF-κB signaling(2023)
Authors: Ginevra Doglioni, Alex Cuadros, Xiaozheng Liu, dorien Broekaert, Sofie Demeyer, Xander Spotbeen, Margherita Demicco, François Richard, Tatjana Geukens, Maxim De Schepper, et al.
Pages: 344 - + - An adverse tumor-protective effect of IDO1 inhibition(2023)
Authors: Chris Marine
- Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1(+) T lymphocyte niches through a feed-forward loop (vol 40, pg 1600, 2022)(2023)
Authors: Yichao Hua, Ann Smeets, David Nittner, Francesca Bosisio, Diether Lambrechts, Chris Marine, Gabriele Bergers
Pages: 226 - 226 - SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response(2022)
Authors: Ewout Landeloos, Yannick Van Herck, Oliver Bechter, Chris Marine
- Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop(2022)
Authors: Yichao Hua, Gerlanda Vella, Ann Smeets, David Nittner, Francesca Bosisio, Beppe Floris, Diether Lambrechts, Chris Marine, Susan Schlenner, Gabriele Bergers
Pages: 1600 - + - Comparative single-cell RNA-sequencing profiling of BMP4-treated primary glioma cultures reveals therapeutic markers(2022)
Authors: Panagiotis Karras, Chris Marine, Danny Huylebroeck
Pages: 2133 - 2145 - p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib (vol 55, pg 98, 2016(2022)
Authors: Chris Marine
Pages: 336 - 338 - Corrigendum to 'p53 Reactivation by PRIMA-1Met (APR-246) sensitises V600E/KBRAF melanoma to vemurafenib'[Eur J of Cancer 55 (2016) 98-110].(2022)
Authors: Chris Marine
Pages: 336 - 338
Patents
1 - 10 of 10
- Inhibition of neat1 for treatment of solid tumors (Inventor)
- Targeting minimal residual disease in cancer with cd36 antagonists (Inventor)
- Direct and selective inhibition of mdm4 for treatment of cancer (Inventor)
- Tumor minimal residual disease stratification (Inventor)
- Targeting minimal residual disease in cancer with rxr antagonists (Inventor)
- Targeting minimal residual disease in cancer with cd36 antagonists (Inventor)
- Targeting minimal residual disease in cancer with rxr antagonists (Inventor)
- Tumor minimal residual disease stratification (Inventor)
- Inhibition of neat1 for treatment of solid tumors (Inventor)
- Inhibition of a lncrna for treatment of melanoma (Inventor)